Pharmacology Researcher from Xi’an People’s Hospital (Xi’an Fourth Hospital), China
Yongpan An is an emerging researcher in the field of pharmacology, specializing in drug screening and the mechanistic study of aging and aging-related diseases. A recent Ph.D. graduate from Peking University, Dr. An has demonstrated significant promise through his contributions to high-impact research, authoring and co-authoring several peer-reviewed publications. His work spans various disciplines, including molecular biology, artificial intelligence, and pharmacological intervention, reflecting a multidisciplinary approach essential for innovative biomedical research. As of now, he is affiliated with Xi’an People’s Hospital, where he continues to build on his doctoral research. Dr. An has already co-authored influential studies published in journals such as Nature Biotechnology, Aging Cell, Frontiers in Pharmacology, and Life Medicine. Despite being early in his career, his scientific output, collaboration with renowned researchers, and peer review responsibilities signal a strong foundation for a successful academic trajectory. His research addresses a critical area in medical science—aging—and aims to identify compounds that can prolong lifespan and reduce age-associated degeneration. With demonstrated leadership in co-authorship roles and contributions to the understanding of pharmacological interventions for aging, Yongpan An stands out as a dedicated, capable, and innovative young scientist poised for further accomplishments.
Professional Profile
Education
Yongpan An’s academic journey reflects a solid foundation in biotechnology and pharmacology, cultivated through rigorous training at leading Chinese institutions. He began his undergraduate studies in Biotechnology at Yunnan University, where he developed fundamental skills in molecular biology and biochemical research. From 2014 to 2018, he was immersed in coursework and research that exposed him to laboratory techniques and foundational knowledge in life sciences. His pursuit of advanced studies led him to Peking University, one of China’s most prestigious academic institutions, where he obtained his Ph.D. in Pharmacology between 2018 and 2023. At Peking University, under the mentorship of Dr. Zhengwei Xie, he focused on drug screening and the molecular mechanisms underlying aging. During this period, Dr. An gained hands-on experience with advanced pharmacological methodologies, contributing to several high-impact studies. His doctoral training not only equipped him with scientific expertise but also fostered skills in critical thinking, interdisciplinary collaboration, and scientific communication. His research incorporated cutting-edge areas such as the application of artificial intelligence in drug discovery, reinforcing the modern relevance of his education. This academic progression—from biotechnology to pharmacology—provides a robust framework for his current and future research endeavors in aging and age-related diseases.
Professional Experience
Dr. Yongpan An is currently employed at Xi’an People’s Hospital, where he continues to engage in pharmacological research with a focus on aging and age-related diseases. Although early in his professional career, Dr. An has already demonstrated remarkable productivity and leadership in scientific research. During his doctoral studies at Peking University, he was deeply involved in collaborative projects that combined pharmacological experimentation with computational analysis. His work involved both in vivo and in vitro models, providing him with experience across various experimental platforms. In addition to research responsibilities, Dr. An served as a reviewer for the journal Pharmacological Research, evaluating scientific manuscripts and gaining familiarity with the editorial and peer-review process. His professional engagements have also included active participation in scientific conferences and forums, where he presented his findings and interacted with experts in the field of aging and pharmacology. Notably, he played a major role in authoring a comprehensive review titled The Landscape of Aging, where he was responsible for summarizing the application of artificial intelligence in anti-aging drug discovery. As he transitions from a student to an independent researcher, Dr. An continues to demonstrate commitment to excellence, innovation, and scientific rigor in his ongoing professional endeavors.
Research Interests
Dr. Yongpan An’s primary research interests lie in the pharmacological modulation of aging and the discovery of novel compounds targeting aging-related diseases. His work integrates drug screening techniques with the mechanistic study of cellular and organismal aging processes. Specifically, he is interested in understanding how small molecules interact with key molecular pathways, such as the AKT signaling cascade, p16, and cyclin regulatory mechanisms, to delay senescence and promote healthy lifespan extension. Another key area of interest for Dr. An is the use of natural products, such as oridonin and berberine, in regulating cellular aging. His contributions to this field are evident from his publications in high-impact journals that explore the therapeutic potential of such compounds in mouse and yeast models. Additionally, he has contributed to the development of AI-driven tools for predicting drug efficacy from transcriptional profiles, showcasing his interest in computational pharmacology. The integration of artificial intelligence and deep learning with experimental pharmacology highlights his vision of combining traditional experimental approaches with cutting-edge digital methodologies. His overarching goal is to discover and validate compounds that not only extend lifespan but also improve quality of life by mitigating the effects of chronic and degenerative diseases associated with aging.
Research Skills
Dr. Yongpan An possesses a diverse and interdisciplinary set of research skills, developed through years of academic training and hands-on laboratory experience. He is proficient in a wide range of pharmacological and molecular biology techniques, including cell culture, Western blotting, immunofluorescence, RNA extraction, and quantitative PCR. He has extensive experience working with animal models, especially in the context of lifespan and senescence studies in mice and yeast, which are central to his research in aging. His capabilities also include the screening and identification of bioactive compounds using high-throughput methods, allowing him to evaluate the pharmacodynamic and pharmacokinetic properties of candidate molecules. Dr. An is adept at using bioinformatics and artificial intelligence tools to analyze gene expression data and predict drug responses. This skillset was crucial in his involvement in the development of deep learning models for drug efficacy prediction, published in Nature Biotechnology. Moreover, his experience as a peer reviewer reflects his ability to critically assess scientific literature and evaluate experimental design, data quality, and interpretation. His collaborative skills and familiarity with interdisciplinary projects further enhance his research capabilities, making him an asset to both academic and clinical research teams focusing on anti-aging pharmacological interventions.
Awards and Honors
Despite being at the beginning of his career, Dr. Yongpan An has already received several prestigious awards in recognition of his academic excellence and research achievements. During his doctoral studies at Peking University, he was honored with the National Scholarship, a highly competitive award given to outstanding students in China. He also received the First Prize in the Soaring Young Scholar competition held by Northwestern Polytechnical University, which recognizes young researchers for innovative scientific contributions. Additionally, he was awarded the Second Prize at the Young Scientist Forum Report organized by the Beijing Society of Pharmacology and Physiological Sciences, affirming his potential as a promising figure in pharmacological research. These honors not only reflect his dedication to scientific inquiry but also underscore the impact and relevance of his work within the research community. His involvement as a co-first author in significant collaborative publications further demonstrates peer recognition of his scholarly efforts. Beyond awards, his service as a manuscript reviewer for an established journal like Pharmacological Research highlights the trust placed in his scientific judgment. Collectively, these accolades validate Dr. An’s emerging role as a capable and committed young scientist with a promising future in pharmacology and aging research.
Conclusion
In summary, Dr. Yongpan An embodies the qualities of a highly promising early-career researcher with a strong academic foundation, impactful research output, and growing recognition within the scientific community. His work focuses on one of the most critical areas in medical science—understanding and intervening in the aging process to improve human health and longevity. His background in both experimental pharmacology and artificial intelligence places him at the intersection of innovation and translational medicine. Despite his relatively recent graduation, he has already authored multiple first-author publications, participated in high-level collaborative research, and received awards for his contributions. Dr. An’s dedication to advancing the pharmacological understanding of aging-related diseases and his proactive engagement in academic publishing and peer review highlight his scientific maturity. He is currently well-positioned to expand his research, attract future funding, and lead independent projects that will further enhance his professional profile. As he continues to build his research portfolio at Xi’an People’s Hospital, Dr. An is likely to contribute significantly to the development of therapeutic strategies that target aging and its associated disorders. Therefore, he represents an outstanding candidate for recognition through awards that honor excellence in scientific research.
Publications Top Notes
- Title: Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy
Authors: Gao, Ke; Xi, Wenjin; Ni, Jianxin; Zhang, Rui; Wu, Guojun
Journal: Biomaterials
Year: 2025